Abivax CEO Signals No Rush for M&A Deals Ahead of Key June Clinical Data

Key Facts

1Abivax CEO Marc de Garidel stated the company is in no rush to secure takeover or partnership deals currently.

2The company expects key clinical trial data in June (Q2), which could strengthen its negotiating position.

3Abivax is considered a prime takeover target in the French biotech sector according to analysts.

Abivax CEO Marc de Garidel has stated that the company is currently in no rush to secure takeover or partnership deals. Speaking to CNBC, de Garidel emphasized that the firm is waiting for crucial clinical trial data expected in June to guide its next strategic steps. The management believes that positive results from these trials will significantly strengthen the company's negotiating position with potential suitors. Analysts currently view Abivax as a prime acquisition target within the French biotechnology sector due to its promising drug pipeline. This strategic patience suggests internal confidence in the upcoming data, aiming to maximize shareholder value before any formal transaction. Market participants are closely monitoring Abivax shares (ABVX) as the second-quarter clinical milestone approaches.